(Q56974069)

English

Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors

article by Susanne J. Pedersen et al published 18 July 2010 in Clinical Rheumatology

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors (English)

0 references

0 references

0 references

Chitinase 3 like 1

1 reference

based on heuristic

inferred from title

Susanne J. Pedersen

object named as

Susanne Juhl Pedersen

1

0 references

Merete Lund Hetland

object named as

Merete Lund Hetland

2

0 references

Hans Jørgen Nielsen

object named as

Hans Jørgen Nielsen

5

0 references

Inge Juul Sørensen

3

object named as

Inge Juul Sørensen

0 references

author name string

Mikkel Østergaard

4

0 references

Julia Sidenius Johansen

6

0 references

publication date

18 July 2010

0 references

Clinical Rheumatology

0 references

29

0 references

11

0 references

1301-1309

0 references

Ankylosing spondylitis: an overview

1 reference

https://api.crossref.org/works/10.1007%2FS10067-010-1528-X

21 January 2018

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept in the longterm treatment of patients with ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adaptation of the Bath measures on disease activity and function in ankylosing spondylitis into Danish

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

What do biomarkers tell us about the pathogenesis of ankylosing spondylitis?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Psoriatic arthritis: epidemiology, clinical features, course, and outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period

1 reference

https://pubmed.ncbi.nlm.nih.gov/20640910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10067-010-1528-X

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56974069&oldid=1739732051"